These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 21007328)
1. Carcinoma of the prostate gland, and benefits of diethylstilbestrol or orchiectomy. WATTENBERG CA Mo Med; 1945 Aug; 42():482-5. PubMed ID: 21007328 [No Abstract] [Full Text] [Related]
2. Bone changes and variations in skeletal metastases due to diethylstilbestrol and orchiectomy during treatment of cancer of the prostate. WATTENBERG CA J Urol; 1947 Nov; 58(5):378-83. PubMed ID: 20270530 [No Abstract] [Full Text] [Related]
3. The effect of castration and di-ethyl stilboestrol in a patient with myelophthisic anemia secondary to carcinoma of the prostate. COMMONS RR; STRAUSS MB J Clin Invest; 1947 Nov; 26(6):1178. PubMed ID: 20272558 [No Abstract] [Full Text] [Related]
4. Myelophthisic anemia the presenting manifestation of prostatic carcinoma with skeletal metastases; the effect of castration and stilbestrol. COMMONS RR; STRAUSS MB Am J Med Sci; 1948 May; 215(5):525-9. PubMed ID: 18101771 [No Abstract] [Full Text] [Related]
5. The effects of castration and stilboestrol on prostatic tumours in mice. HORNING ES Br J Cancer; 1949 Jun; 3(2):211-30. PubMed ID: 18132112 [No Abstract] [Full Text] [Related]
6. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. Jordan WP; Blackard CE; Byar DP South Med J; 1977 Dec; 70(12):1411-3. PubMed ID: 594790 [TBL] [Abstract][Full Text] [Related]
7. Bilateral orchiectomy in the management of stage D-2 prostate cancer. Guinan P; Firfer R; Targonski P; Rubenstein M Int Surg; 1993; 78(1):73-5. PubMed ID: 8473090 [TBL] [Abstract][Full Text] [Related]
14. Influence of diethylstilbestrol, Leuprolelin (a luteinizing hormone-releasing hormone analog), Finasteride (a 5 alpha-reductase inhibitor), and castration on the lobar subdivisions of the rat prostate. Yamashita A; Hayashi N; Sugimura Y; Cunha GR; Kawamura J Prostate; 1996 Jul; 29(1):1-14. PubMed ID: 8685049 [TBL] [Abstract][Full Text] [Related]
15. Current management of prostatic carcinoma. Bahnson RR; Catalona WJ Prim Care; 1985 Dec; 12(4):795-813. PubMed ID: 3909178 [TBL] [Abstract][Full Text] [Related]
16. A NEW PITUITARY-INHIBITING COMPOUND IN THE TREATMENT OF PROSTATIC CANCER. NYLANDER G; TERNER N Urol Int; 1964; 17():129-45. PubMed ID: 14168016 [No Abstract] [Full Text] [Related]
17. EORTC protocol 30805: a phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Robinson MR Prog Clin Biol Res; 1988; 260():101-10. PubMed ID: 2966402 [No Abstract] [Full Text] [Related]
18. Complete androgen blockade: the EORTC experience comparing orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate. Robinson MR Prog Clin Biol Res; 1987; 243A():383-90. PubMed ID: 2958863 [No Abstract] [Full Text] [Related]
19. [Combined hormone and chemotherapy for the patients with advanced prostate cancer]. Uekado Y; Hirano A; Inagaki T; Hiroi A; Watanabe T Gan To Kagaku Ryoho; 1995 Jul; 22(8):1041-5. PubMed ID: 7611755 [TBL] [Abstract][Full Text] [Related]
20. Hormone chemotherapy for newly diagnosed patients with metastatic prostate cancer. Kubota Y; Nakada T; Suzuki Y; Iizima Y; Adachi Y; Hashimoto T Int Urol Nephrol; 1993; 25(5):469-74. PubMed ID: 8270375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]